Skip to content
Screener

Exelixis EXEL Net Income

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.1B+25.3%
Pfizer logo
PfizerPFE
-$248M-109%
Kura Oncology logo
Kura OncologyKURA
-$73.33M-27.7%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$45.51M-14.1%
Immunome logo
ImmunomeIMNM
-$53.84M-29.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$91M

Segments

By segment

See full
Reportable Segment$212.05M+14.7%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other income (expenses), net5450273(195)
Income before income taxes262,678230,415530,365436,105
Provision for income taxes50,62845,567107,84891,641
Net income$212,050$184,848$422,517$344,464
Net income per share:
Basic$0.85$0.68$1.66$1.25
Diluted$0.82$0.65$1.60$1.20
Weighted-average common shares outstanding:

Item 1. Financial Statements.

FAQ

What is Exelixis's net income?
Exelixis (EXEL) reported net income of $212.05M in Q2 2026.
How has Exelixis's net income changed year-over-year?
Exelixis's net income increased by 14.7% year-over-year, from $184.85M to $212.05M.
What is the long-term trend for Exelixis's net income?
Over 3 years (2021 to 2025), Exelixis's net income has grown at a 50.2% compound annual growth rate (CAGR), from $231.06M to $782.57M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Exelixis's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude